B Riley FBR

Weight Watchers International, Inc. (NYSE: WTW) reported an earnings beat in its second-quarter results, which may have been overshadowed by a slowdown in subscriber growth. Here's a summary of how some Street analysts reacted to the report. The Analysts D.A. Davidson's Linda Bolton Weiser...

With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners.  The Analyst Analyst George Zavoico initiated coverage of Pluristem Therapeutics Inc. (NASDAQ: PSTI)...

Farmland Partners Inc (NYSE: FPI) dropped 39 percent Wednesday on negative rumors about its loan program, solvency, valuation and reliance on external sources of capital, among other factors. The Analyst B. Riley FBR analyst Craig Kucera upgraded Farmland Partners from Neutral to Buy and cut...

Broadcom Inc (NASDAQ: AVGO) moved 15 percent lower Thursday on mixed reactions following the announcement it had reached a deal to acquire CA, Inc. (NASDAQ: CA). CA Inc. (also known as CA Technologies) jumped 18 percent higher, realizing most of the 20 percent premium to the July 11 closing price...

Arbutus Biopharma Corp (NASDAQ: ABUS) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally.   The Analyst B. Riley FBR's Madhu Kumar downgraded Arbutus Biopharma from Buy to Neutral with an unchanged $...

Nano-cap pharma company Alimera Sciences Inc (NASDAQ: ALIM) could nearly triple in value for three key reasons, according to B. Riley FBR.  The Analyst Analyst Andrew D'Silva initiated coverage of Alimera Sciences with a Buy rating and $2.75 price target. The Thesis Alimera is a...

Uniqure NV (NASDAQ: QURE), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. The Analyst B. Riley FBR's Madhu Kumar initiated coverage of Uniqure with a Buy rating and $50 price target....

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) lost a sell-side bull Tuesday, with a B. Riley FBR analyst praising the company's pipeline but concluding the biotech's positives are priced into the stock. The Analyst B. Riley FBR's Madhu Kumar downgraded Deciphera from Buy to Neutral. The...